Edition:
India

Cipla Ltd (CIPL.BO)

CIPL.BO on Bombay Stock Exchange

622.60INR
23 Jan 2018
Change (% chg)

Rs21.50 (+3.58%)
Prev Close
Rs601.10
Open
Rs598.30
Day's High
Rs625.00
Day's Low
Rs598.30
Volume
258,630
Avg. Vol
111,141
52-wk High
Rs663.00
52-wk Low
Rs479.00

Latest Key Developments (Source: Significant Developments)

Kiadis Pharma Proposes Subhanu Saxena, Former Cipla CEO, As New Supervisory Board Member
Tuesday, 16 Jan 2018 

Jan 16 (Reuters) - KIADIS PHARMA NV ::KIADIS PHARMA PROPOSES FORMER CIPLA CEO SUBHANU SAXENA AS NEW SUPERVISORY BOARD MEMBER.SUPERVISORY BOARD WILL NOMINATE SUBHANU SAXENA TO BE APPOINTED AS NEW MEMBER OF SUPERVISORY BOARD​.  Full Article

Cipla Launches Q-Tib Globally
Thursday, 30 Nov 2017 

Nov 30 (Reuters) - Cipla Ltd ::SAYS CIPLA LAUNCHES Q-TIB GLOBALLY.SAYS GOT APPROVAL FOR PRODUCT Q-TIB FROM WORLD HEALTH ORGANISATION.Q-TIB WILL HELP PREVENT TUBERCULOSIS INFECTION IN PEOPLE LIVING WITH HIV.  Full Article

Cipla gets final approval for generic Dacogen​
Monday, 20 Nov 2017 

Nov 20 (Reuters) - Cipla Ltd :Says ‍Cipla receives final approval for generic Dacogen​.Drug indicated for treatment of patients with myelodysplastic syndromes.Product is available for shipping immediately.  Full Article

Cipla gets final approval for generic Pulmicort Respules
Friday, 17 Nov 2017 

Nov 17 (Reuters) - Cipla Ltd ::Cipla receives final approval for generic Pulmicort Respules.Drug indicated for maintenance treatment of asthma, as prophylactic therapy in children 12 months to 8 years of age.Product available for shipping immediately.  Full Article

India's Cipla Sept qtr consol profit up about 19 pct
Tuesday, 7 Nov 2017 

Nov 7 (Reuters) - Cipla Ltd :Sept quarter consol net profit 4.23 billion rupees versus profit of 3.54 billion rupees last year.Consensus forecast for sept quarter consol net profit was 4.20 billion rupees.Sept quarter consol net sales 39.88 billion rupees versus 36.72 billion rupees last year.  Full Article

Cipla says US unit gets USFDA final approval for generic Renvela tablets‍​
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Cipla Ltd :Says us subsidiary receives final approval for generic Renvela tablets‍​.  Full Article

Cipla's U.S. unit gets final FDA nod for generic Renvela tablets
Friday, 27 Oct 2017 

Oct 27 (Reuters) - Cipla Ltd ::Says co's U.S. unit gets final FDA nod for generic Renvela tablets ‍​.  Full Article

India's Cipla March-qtr loss narrows
Thursday, 25 May 2017 

May 25 (Reuters) - Cipla Ltd :Consol March quarter net loss 617.9 million rupees.Consol march quarter total income from operations 35.82 billion rupees.Recommended payment of dividend of 2 rupees per share.Consol net loss in March quarter last year was 928.3 million rupees as per Ind-AS; consol total income from operations was 33.15 billion rupees.  Full Article

Cipla gets EIR from USFDA for its Indore facility
Wednesday, 12 Oct 2016 

Cipla Ltd :Cipla receives EIR from the US FDA for its Indore facility.  Full Article

Cipla Ltd exec says co expects about 200 mln rupees of impact from FDC ban, NLEM in Q2
Friday, 12 Aug 2016 

Cipla Ltd : Cipla's Samina Vaziralli says "the family is completely committed", "absolutely no prospect" of selling the company . Exec says expects about 200 million rupees of impact from FDC ban and NLEM in Q2 . Further company coverage [CIPL.NS] ((Bangalore.newsroom@thomsonreuters.com)).  Full Article

BRIEF-Kiadis Pharma Proposes Subhanu Saxena, Former Cipla CEO, As New Supervisory Board Member

* KIADIS PHARMA PROPOSES FORMER CIPLA CEO SUBHANU SAXENA AS NEW SUPERVISORY BOARD MEMBER